|
|
News Breaks | | | | March 21, 2013 | | 07:30 EDT |  | INCY | Incyte pullback a buying opportunity, says Piper Jaffray
Piper Jaffray views the pullback in Incyte shares after the company disclosed that a patient treated with Jakafi developed a case of PML as a buying opportunity. After speaking with management, Piper said it has increased confidence that the case of PML is unlikely Jakafi related. The firm believes Jakafi’s sales ramp remains intact and raised its price target for Incyte shares to $27 from $23 while keeping an Overweight rating on the stock. | |
|
News For INCY From The Last 14 Days Check below for free stories on INCY the last two weeks. |
|
|
| May 7, 2013 | | 06:23 EDT |  | INCY | Incyte coverage resumed with a Sell at Goldman
Target $17. | |
|
|
|
|
|
|
